Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $4.4 in the prior trading day, Altimmune Inc (NASDAQ: ALT) closed at $4.14, down -5.91%. In other words, the price has decreased by -$5.91 from its previous closing price. On the day, 4.12 million shares were traded. ALT stock price reached its highest trading level at $4.35 during the session, while it also had its lowest trading level at $4.1.
Ratios:
Our goal is to gain a better understanding of ALT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.82 and its Current Ratio is at 15.82. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On January 08, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $18.Stifel initiated its Buy rating on January 08, 2025, with a $18 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 17 ’25 when Sohn Catherine A. bought 1,000 shares for $5.78 per share. The transaction valued at 5,784 led to the insider holds 1,000 shares of the business.
WEAVER GREGORY L bought 10,000 shares of ALT for $51,996 on Mar 13 ’25. The Chief Financial Officer now owns 10,000 shares after completing the transaction at $5.20 per share. On Aug 19 ’24, another insider, Drutz David, who serves as the Director of the company, sold 16,011 shares for $6.90 each. As a result, the insider received 110,547 and left with 41,958 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALT now has a Market Capitalization of 335782976 and an Enterprise Value of 165644992. For the stock, the TTM Price-to-Sale (P/S) ratio is 16789.00 while its Price-to-Book (P/B) ratio in mrq is 2.27. Its current Enterprise Value per Revenue stands at 8282.249 whereas that against EBITDA is -1.69.
Stock Price History:
The Beta on a monthly basis for ALT is -0.00, which has changed by -0.47594935 over the last 52 weeks, in comparison to a change of 0.1116153 over the same period for the S&P500. Over the past 52 weeks, ALT has reached a high of $11.16, while it has fallen to a 52-week low of $2.90. The 50-Day Moving Average of the stock is -26.05%, while the 200-Day Moving Average is calculated to be -35.38%.
Shares Statistics:
The stock has traded on average 5.44M shares per day over the past 3-months and 9892890 shares per day over the last 10 days, according to various share statistics. A total of 81.11M shares are outstanding, with a floating share count of 80.26M. Insiders hold about 1.04% of the company’s shares, while institutions hold 47.45% stake in the company. Shares short for ALT as of 1749772800 were 24400612 with a Short Ratio of 5.73, compared to 1747267200 on 22671188. Therefore, it implies a Short% of Shares Outstanding of 24400612 and a Short% of Float of 30.320000000000004.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The market rating of Altimmune Inc (ALT) is currently shaped by the ongoing analysis conducted by 7.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.33, with high estimates of -$0.25 and low estimates of -$0.37.
Analysts are recommending an EPS of between -$1.02 and -$1.38 for the fiscal current year, implying an average EPS of -$1.27. EPS for the following year is -$1.56, with 5.0 analysts recommending between -$1.37 and -$1.89.
